Somerset, N.J. – November 11, 2016 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Wetteny Joseph, President, Clinical Supply Services, will be presenting at the upcoming Clinical Trials Supply Southern California 2016 Conference, to be held at the Hyatt Regency La Jolla at Aventine Hotel, San Diego, on Nov. 15 – 16, 2016.
Mr. Joseph’s presentation, on Tuesday, Nov. 15 at 11:30 a.m., is entitled “Clinical Trial Supply Strategies for Small and Mid-size Biopharma Sponsors,” and will discuss how material supply becomes more complex through the later stages of clinical development, and entails sponsors facing multiple logistical considerations. Some of these challenges include complicated study protocols, blinding and randomization, comparator sourcing, moving from a single locale to multi-national studies and cold chain distribution. The session will also explore the obvious and not-so-obvious issues that need to be addressed to better inform and develop a robust and efficient clinical supply strategy.
Mr. Joseph was named President, Clinical Supply Services, in October 2015. He first joined Catalent in 2008 as Corporate Controller, and in 2012, was charged with leading the finance function for the company’s modified release technologies. In 2013, Mr. Joseph was promoted to Vice President of Finance for the organization’s Development and Clinical Services division, incorporating clinical supply services. Before joining Catalent, Mr. Joseph held senior financial positions at HD Supply, including as CFO of a $1.2 billion business unit. He also served as Corporate Controller at Hughes Supply, a Fortune 500 company. In his early career, Mr. Joseph spent six years at PricewaterhouseCoopers as an auditor, and as a strategic financial advisor across a variety of industries. Mr. Joseph earned both his master’s and bachelor’s degrees in accounting from Florida Atlantic University.
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 9,500 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2016 generated $1.85 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com